BGNE - BeiGene, Ltd.
| Previous Close | 128.34 |
| Open | 128.82 |
| Bid | 126.69 x 1000 |
| Ask | 137.50 x 800 |
| Day's Range | 126.33 - 130.59 |
| 52 Week Range | 105.19 - 220.10 |
| Volume | 242,295 |
| Avg. Volume | 302,720 |
| Market Cap | 7.634B |
| Beta (3Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -12.83 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 184.28 |
- GlobeNewswire•9 days ago
BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association
CAMBRIDGE, Mass. and BEIJING, China, May 16, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Reuters•16 days ago
BRIEF-Beigene Posts Qtrly Net Loss Attributable Of $167.6 Million
May 10 (Reuters) - Beigene Ltd: * QTRLY NET LOSS ATTRIBUTABLE TO BEIGENE, LTD. $167.6 MILLION VERSUS LOSS OF $104.6 MILLION * QTRLY TOTAL REVENUES $77.8 MILLION VERSUS $32.5 MILLION Source text for Eikon: ...
- Reuters•16 days ago
BRIEF-BeiGene Q1 Loss Per Share $0.22
May 9 (Reuters) - Beigene Ltd: * BEIGENE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS * Q1 LOSS PER SHARE $0.22 * COLLABORATION REVENUE TOTALED $20.41 MILLION FOR Q1 ENDED MARCH 31, 2019, COMPARED TO $9.29 ...
- GlobeNewswire•16 days ago
BeiGene Reports First Quarter 2019 Financial Results
CAMBRIDGE, Mass. and BEIJING, China, May 09, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Simply Wall St.•26 days ago
Is BeiGene, Ltd. (NASDAQ:BGNE) Trading At A 24% Discount?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! How far off is BeiGene, Ltd. (NASDAQ:BGNE) from its intrinsic value? Using the most recent financial...
- Reuters•27 days ago
BRIEF-Beigene Ltd Says CEO's Total Compensation For FY 2018 Was $27.9 Mln Versus $10.3 Mln In FY 2017
April 29 (Reuters) - Beigene Ltd: * BEIGENE LTD SAYS CEO JOHN V. OYLER'S TOTAL COMPENSATION FOR FY 2018 WAS $27.9 MILLION VERSUS $10.3 MILLION IN FY 2017- SEC FILING * BEIGENE LTD SAYS GENERAL MANAGER ...
- Insider Monkey•2 months ago
Here’s What Hedge Funds Think About BeiGene, Ltd. (BGNE)
The Insider Monkey team has completed processing the quarterly 13F filings for the December quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors endured a torrid quarter, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As […]
- GlobeNewswire•2 months ago
BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the two companies have entered into a global co-development and collaboration agreement for the development, manufacturing and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071). BA3071 is a novel, CTLA-4 inhibitor that is designed to be conditionally activated in the tumor microenvironment in order to reduce systemic toxicity and potentially enable safer combinations with checkpoint inhibitors such as BeiGene’s investigational anti-PD-1 antibody, tislelizumab, a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages.
- MarketWatch•2 months ago
Micron Technology, Tencent and two dozen other companies most likely to benefit from a China trade deal
Investors have been holding back until President Trump’s negotiators complete talks with the world’s most populous nation.
- GlobeNewswire•2 months ago
BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the presentation of long-term Phase 1 data and results of structural and binding mechanistic analyses on its investigational anti-PD1 inhibitor, tislelizumab, in two posters at the American Association for Cancer Research (AACR) Annual Meeting 2019, taking place March 29-April 3, 2019, in Atlanta, Georgia. “We believe that these two presentations further support the broad development program for tislelizumab as a potentially differentiated anti-PD1 antibody,” said Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology, at BeiGene.
- Simply Wall St.•2 months ago
Does BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Pay Matter?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! John Oyler has been the CEO of BeiGene, Ltd. (NASDAQ:BGNE) since 2010. This analysis aims first to contrast CEO co...
- Motley Fool•2 months ago
3 Key Takeaways From BeiGene's CEO
China's biotech industry is growing quickly, and the innovative BeiGene could be an opportunity in the space.
- MarketWatch•3 months ago
Be cautious about the market now — and buy these 3 stocks on weakness
It's time to get a bit more cautious about stocks now for two reasons: Investor sentiment has ramped up and the markets are overbought. Virtually all of the dozen or so sentiment indicators I track were recently either neutral or bearish. One saving grace for the bulls is that the Investors Intelligence Bull/Bear ratio, a key indicator I track, has recently hovered around 2.57.
- Reuters•3 months ago
BRIEF-Ambrx And Beigene Announce Global Research And Development Collaboration To Develop Next-Generation Biologics
March 6 (Reuters) - Beigene Ltd: * AMBRX AND BEIGENE ANNOUNCE GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION TO DEVELOP NEXT-GENERATION BIOLOGICS * BEIGENE LTD - UNDER TERMS, AMBRX WILL RECEIVE AN UPFRONT ...
- GlobeNewswire•3 months ago
Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics
Ambrx to receive an upfront payment of US$10 million to apply its proprietary Expanded Genetic Code platforms to discover novel biologic drug candidates in this collaboration.
- GlobeNewswire•3 months ago
Consolidated Research: 2019 Summary Expectations for TherapeuticsMD, Ensco plc, Cray, BeiGene, The Gap, and Nordson — Fundamental Analysis, Key Performance Indications
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- GlobeNewswire•3 months ago
BeiGene to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., and BEIJING, China, March 04, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of BGNE earnings conference call or presentation 27-Feb-19 11:00pm GMT
Q4 2018 Beigene Ltd Earnings Call
- Zacks•3 months ago
Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018
Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.
- Zacks•3 months ago
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4
Intrexon (XON) incurs narrower-than-expected loss in the fourth quarter of 2018.
- Zacks•3 months ago
Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat
Horizon Pharma's (HZNP) earnings and sales beat estimates in the fourth quarter of 2018.
- Reuters•3 months ago
BRIEF-Beigene Reports Qtrly Loss Per Share Of $0.35
Feb 27 (Reuters) - Beigene Ltd: * BEIGENE REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS * BEIGENE LTD QTRLY NET LOSS PER ADS ATTRIBUTABLE TO BEIGENE LTD $4.52 * BEIGENE LTD QTRLY LOSS PER ...
- GlobeNewswire•3 months ago
BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results
Company to Host Annual Results Conference Call Today at 6:00 p.m. EST and Investor Event in Hong Kong on February 28th at 2:30 p.m. HKT CAMBRIDGE, Mass. and BEIJING, China,.
- ACCESSWIRE•3 months ago
BeiGene Ltd. Sponsored ADR to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2019 / BeiGene Ltd. Sponsored ADR (NASDAQ: BGNE ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 27, 2019 ...
- GlobeNewswire•3 months ago
BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass. and BEIJING, China, Feb. 22, 2019 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
